In short
Isaralgagene Civaparvovec, also known as ST-920, is an innovative gene therapy being studied in clinical trials for the treatment of Fabry Disease. This article will provide an overview of the ongoing research, including the study objectives, eligibility criteria, and potential benefits for patients with this rare genetic disorder.
At a glance
- Study Type
- Phase I/II, Multicenter, Open-Label, Single-Dose, Dose-Ranging
- Main Objective
- Assess safety and tolerability of ST-920
- Secondary Objectives
- Evaluate enzyme activity, substrate levels, impact on ERT, renal and cardiac function
- Key Eligibility Criteria
- Adults (≥18 years) with Fabry Disease diagnosis, specific criteria for different cohorts
- Treatment Administration
- Single-dose intravenous injection/infusion
- Primary Endpoints
- Incidence of treatment-emergent adverse events, safety evaluations
- Secondary Endpoints
- Changes in enzyme activity, substrate levels, ERT frequency, organ function
What is ISARALGAGENE CIVAPARVOVEC?
ISARALGAGENE CIVAPARVOVEC, also known as ST-920, is an innovative gene therapy being developed to treat Fabry disease. It is a recombinant adeno-associated virus 2/6 vector that carries the genetic code for producing a crucial enzyme missing in people with Fabry disease. This treatment is currently being studied in clinical trials to assess its safety and effectiveness.
Fabry Disease: An Overview
Fabry disease is a rare genetic disorder classified as an X-linked lysosomal storage disease. People with this condition lack or have insufficient amounts of an enzyme called alpha-galactosidase A (α-Gal A). This deficiency leads to the buildup of certain fatty substances in various organs, causing a wide range of symptoms and complications.
Some common symptoms of Fabry disease include:
- Cornea verticillata (clouding of the eye's cornea)
- Acroparesthesia (burning pain in hands and feet)
- Anhidrosis (decreased ability to sweat)
- Angiokeratoma (small, dark red spots on the skin)
How ISARALGAGENE CIVAPARVOVEC Works
ISARALGAGENE CIVAPARVOVEC is designed to deliver a functional copy of the GLA gene, which codes for the α-Gal A enzyme, directly to the patient's cells. The treatment uses a modified virus (AAV2/6) as a vehicle to carry this genetic material. Once inside the body, the goal is for the cells to use this new genetic information to produce the missing enzyme, potentially alleviating the symptoms of Fabry disease.
Clinical Trial Information
The ongoing clinical trial for ISARALGAGENE CIVAPARVOVEC is a Phase I/II study aimed at assessing the safety and tolerability of the treatment in patients with Fabry disease. Here are some key points about the trial:
- It is a multicenter, open-label, single-dose, dose-ranging study.
- The main objective is to evaluate the safety and tolerability of ST-920.
- Secondary objectives include assessing the treatment's impact on α-Gal A activity, enzyme replacement therapy (ERT) requirements, renal function, and cardiac function.
- The study will also monitor the presence of the vector in various bodily fluids over time.
Potential Benefits
If successful, ISARALGAGENE CIVAPARVOVEC could offer several potential benefits for Fabry disease patients:
- Increased α-Gal A enzyme activity in the body
- Reduction in harmful substance accumulation (Gb3 and lyso-Gb3) in plasma
- Possible reduction in the frequency of enzyme replacement therapy (ERT) infusions
- Potential improvements in kidney function
- Possible enhancements in heart function and structure
Safety and Side Effects
As with any new treatment, safety is a primary concern. The clinical trial is closely monitoring for any adverse events. Some areas of focus include:
- Routine blood tests to check for any changes in blood cell counts or organ function
- Regular heart monitoring through ECG and echocardiogram
- Liver function tests and imaging to ensure liver health
- Monitoring for any immune reactions to the treatment
Who is Eligible for the Treatment?
The clinical trial has specific eligibility criteria. Some key points include:
- Patients must be 18 years or older
- Diagnosed with Fabry disease
- May be on enzyme replacement therapy (ERT) or ERT-naïve
- Must have certain Fabry disease symptoms
- Specific criteria for different study cohorts (e.g., renal function requirements for the renal cohort)
There are also several exclusion criteria, such as certain medical conditions or treatments that might interfere with the study results or pose additional risks.
How is the Treatment Administered?
ISARALGAGENE CIVAPARVOVEC is administered as a single intravenous (IV) infusion. This means the treatment is given directly into a vein, typically in a controlled medical setting. After administration, patients are closely monitored for any immediate reactions and to track the treatment's effectiveness over time.
Conclusion
ISARALGAGENE CIVAPARVOVEC represents a promising advancement in the treatment of Fabry disease. As a gene therapy, it aims to address the root cause of the condition by providing the body with the ability to produce the missing enzyme. While the treatment is still in clinical trials and more research is needed to fully understand its long-term effects and benefits, it offers hope for improved management of Fabry disease in the future.